US6300309B1 - Method and composition for the treatment of osteoporosis - Google Patents
Method and composition for the treatment of osteoporosis Download PDFInfo
- Publication number
- US6300309B1 US6300309B1 US08/243,520 US24352094A US6300309B1 US 6300309 B1 US6300309 B1 US 6300309B1 US 24352094 A US24352094 A US 24352094A US 6300309 B1 US6300309 B1 US 6300309B1
- Authority
- US
- United States
- Prior art keywords
- mammal
- igf
- mineral density
- bone mineral
- cortical bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title abstract description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 49
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 46
- 241000124008 Mammalia Species 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 46
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 34
- 239000011707 mineral Substances 0.000 claims description 34
- 230000001054 cortical effect Effects 0.000 claims description 27
- 230000009467 reduction Effects 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000001739 density measurement Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000010188 recombinant method Methods 0.000 claims description 3
- 230000001850 reproductive effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 description 9
- 206010017076 Fracture Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 239000003708 ampul Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000283089 Perissodactyla Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241001493546 Suina Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000123 anti-resoprtive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010041569 spinal fracture Diseases 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000282418 Hominidae Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- -1 antiinfectives Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention concerns a method for the treatment of higher mammals having or being at substantial risk of developing osteoporosis in cortical bone, the treatment comprising the administration of insulin-like growth factor I (IGF-I).
- IGF-I insulin-like growth factor I
- the invention is directed to the fields of bone growth and degeneration, to IGF-I, and to compositions thereof for use as pharmaceuticals.
- Osteoporosis encompasses a broad range of clinical syndromes having varying etiologies.
- Type I osteoporosis occurs mainly in the early postmenopausal period from about age 50-65. It is characterized by excessive resorption, primarily in trabecular bone. Vertebral fractures are common. If given prior to significant bone loss, treatment which decreases or prevents bone resorption (such as with estrogen or calcitonin) is considered effective therapy.
- Type II osteoporosis (a.k.a. senile osteoporosis) occurs essentially in all aging women and, to a lesser extent, in men. It is characterized by proportionate loss of cortical bone as well as trabecular bone. Here decreased bone formation plays a major role, if not a more important role than increased bone resorption. Fractures of the hip are characteristic of this type of osteoporosis.
- estrogen therapy which is not really an acceptable therapeutic agent for women with a history of or at risk for breast or endometrial cancers (estrogen dependent tumors) or for men with osteoporosis.
- IGF-I Insulin-like Growth Factor I
- IGF-I Insulin-like Growth Factor I
- IGF-I is a 70 amino acid peptide belonging to a family of compounds under the class name somatomedins and retains some structural and biologically similarities to insulin. The somatemedins' activity lie on a spectrum from hypoglycemic effects similar to insulin to growth promoting effects which are exemplified by growth hormone. IGF-I predominately induces growth and cell proliferation. IGF-I has also been demonstrated to specifically bind to receptors on rat osteoblast-like bone cells (Bennett et al, Endocrin. 115(4):1577-1583, 1984). IGF-I is routinely fabricated in the liver and released for binding to carrier proteins in the plasma (Schwander et al, Endocrin.
- IGF-I infused into rats has been shown to result in markedly greater increases in body weight gain compared to controls, with increases in tibial epiphyseal width and thymidine incorporation into costal cartilage (Nature 107: 16-24, 1984) and directly stimulate osteoblasts to result in a greater number of functional osteoblasts.
- IGF-I is also mentioned as the vehicle through which growth hormone's effects on bone is mediated in Simpson, Growth Factors Which Affect Bone, Physiol. 235, TIBS, December 12, 1984.
- an object of the present invention is to provide a method of treatment of osteoporosis in higher mammals exhibiting decreased cortical bone mineral density and preventing osteoporosis due to cortical bone mineral density reduction in such mammals clinically prone to such cortical bone density reductions.
- Another object of the invention is to provide pharmaceutical compositions useful in achieving the foregoing object.
- IGF-I is useful in the treatment of osteoporosis in higher mammals exhibiting decreased cortical bone mineral density and those exposed to drugs or environmental conditions which tend to result in cortical bone mineral density reduction and potentially to a cortical bone osteoporotic condition.
- the present invention concerns osteoporosis treatment and prevention, which osteoporosis is associated with decreased cortical bone mineral density in mammals generally, but is especially suited for the treatment and prevention of such osteoporosis in humans.
- mammals includes all mammals within the taxonomic orders of Primates, Carnivora, Perissodactyla and Artiodactyla. This includes, without limitation, Old World monkeys, New World monkeys, great apes, humans, cats, dogs, horses, pigs, cattle, sheep, and goats. Preferably mammals are selected from the taxonmic orders of Primates, Carnivora, Perissodactyla, and Artiodactyla, more preferably Primates, cats, dogs, sheep, goats, horses, pigs and cattle, still more preferably Primates, most preferably humans.
- IGF-I is a naturally occuring protein that can be obtained from a number of sources.
- IGF-I from the same species (or its synthetic twin) as the species being treated therewith is employed, but IGF-I from one species may be used to treat another species if the immune response elicited is slight or non-existent.
- fragments and analogs of IGF-I having IGF-I activity are also suitably employed in the invention.
- IGF-I includes such fragments and analogs unless the text clearly states otherwise.
- IGF-I analogs and fragments of IGF-I or its analogs are commonly known in the art as can be seen from Proc. Natl. Acad. Sci. USA, Vol 83, pp. 4904-4907, July 1986; Biochemical and Biophysical Research Communications, Vol 149, No. 2, pp. 398-404, Dec. 16, 1987; Biochemical and Biophysical Research Communications, Vol. 149, No. 2, pp. 672-679, Dec. 16, 1987; Endocrinology, Vol. 123, No. 1, pp. 373-381; The Journal of Biological Chemistry, Vol. 263, No. 13, pp. 6233-6239, May 5, 1988; and Biochemical and Biophysical Research Communications, Vol. 165, No. 2, pp. 766-771, Dec. 15, 1989.
- IGF-I can be synthetically produced, chemically or by recombinant techniques, as well as extracted from tissues. Recombinant manufacture is preferred. One such recombinant technique is disclosed in EP 123,228, incorporated herein by reference.
- An effective amount of IGF-I for the present invention is an amount sufficient to slow, stop, or reverse the cortical bone mineral density reduction rate in a patient exhibiting cortical bone mineral density reduction.
- bone mineral density in the spine typically is in the range of 0.85 to 1.9 g/cm 3 , usually 0.9 to 1.85 g/cm 3 , and most 1.0 to 1.8 g/cm 3 ; and in the mid radius and distal radius it is typically 0.7-1.4 g/cm 3 , usually 0.75-1.3 g/cm 3 , and most often 0.8-1.2 g/cm 3 .
- Exemplary non-limiting normal ranges are shown in the Figures along with osteoporosis distributions. Norms using other techniques will be apparent from the literature and general experience therewith as experience with such techniques grow.
- the present invention is directed to treating those with bone mineral which is (a) totally below either the normal bone mineral density range for the population generally or for the patient sub-population or (b) below 1.0 g/cm 3 or (c) below the fracture threshold (approximately 2 standard deviations below the mean bone mass for the population at age 35).
- the fracture threshold for the spine is defined as the bone mineral density value below which 90% of all patients with one or more compression fractures of the spine are found.
- any bone mineral density reduction should be followed for further reductions, which cumulatively may be significant.
- an effective amount of IGF-I when given parentally (intravenously, subcutaneously, intramuscularly, etc.) is between 2.5 ⁇ g/Kg/day up to about 180 ⁇ g/Kg/day, preferably about 5 ⁇ g/Kg/day up to about 150 ⁇ g/Kg/day, more preferably 10 ⁇ g/Kg/day up to about 120 ⁇ g/Kg/day, even more preferably 10 ⁇ g/Kg/day up to about 100 ⁇ g/Kg/day, still more preferably about 10 ⁇ g/Kg/day up to about 90 ⁇ g/Kg/day.
- Such effective amount may be given in two or three doses spread over time such as by IV drip or subcutaneous injection(s) with the total daily dose being spread across a portion or the entire administration period.
- Typical continuous dosing is in the range of 2.5 ⁇ g/Kg/hour up lto about 50 ⁇ g/Kg/hour, preferably about 5 ⁇ g/Kg/hour up to about 25 ⁇ g/Kg/hour, although wider ranges of “continuous” administration amounts will be apparent to those of ordinary skill in the art.
- subcutaneous injection it is most preferably administered from 2 times/wk up to 3 times a day, preferably 3 times a week up to once or twice daily.
- Particularly suitable doses are 10, 15, 30, and 60 ⁇ g/Kg/day.
- the specific dosage for a particular patient has to be adjusted to the degree of response, route of administration, the individual weight and general condition of the patient to be treated, and is finally dependent upon the judgment of the treating physician.
- the pharmaceutical preparations for use in the present invention comprise an effective amount of IGF-I or an active fragment or analog or fragment of an analog thereof together with a pharmaceutically and parentally acceptable carrier or adjuvant.
- Compositions having an approximately 6 day supply typically contain from about 0.1 mg to 15 mg, preferably 1 mg to 13 mg, more preferably about 3 mg to about 10 mg, most preferably 5 mg to 10 mg of IGF-I.
- the liquid carriers are typically sterile water, approximately physiologic saline, about 0.1 M acetic acid, approximately 5% aqueous dextrose, etc; preferably sterile water, physiologic saline, or 5% aqueous dextrose.
- the carriers and adjuvants may be solid or liquid and may be organic or inorganic.
- the active compound and the compositions of the invention are preferably used in the form of preparations or infusions for parenteral (subcutaneous, intramuscular, or intravenous) administration.
- Such solutions are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example by reconstituting a lyophilized preparation of the active agent.
- the pharmaceutical preparations may be sterilized and/or contain adjuvants, for example preservatives, antiinfectives, stabilizers wetting agents, emulsifiers, solubilizers, tonicity regulating agents, and/or buffers.
- adjuvants will of course be apparent to those of ordinary skill in the art.
- Other dosage forms and routes of administration for use in the present invention include aerosols and sprays for lung inhalation or as a nasal spray, transdermal patch administration, and buccal administration.
- the present pharmaceutical preparations which, if desired, may contain further pharmacologically active or otherwise pharmaceutically valuable substances, especially bone antiresorptives such as estrogen, calcitonin, and bisphosphonates, particularly 3-aminopropyl-1hydroxy-1, 1-bisphosphonate, are prepared from their constituent parts by techniques known in the art, for example lyophilization, dissolution, reconstitution, and suspension techniques, among others known to those of ordinary skill. They typically contain from about 0.1% to about 100% of active ingredient, but especially in the case of a solution from about 1% to about 20% and especially in the case of a lyophilizate up to 100% of active ingredient.
- bone antiresorptives such as estrogen, calcitonin, and bisphosphonates, particularly 3-aminopropyl-1hydroxy-1, 1-bisphosphonate
- FIG. 1 Bone mineral density (BMD in spine ( 1 A); (L1-4; measured with use of dual-photon absorptiometry)), midradius ( 1 B), and distal radius ( 1 C) (measured with use of single-photon absorptiometry) in 76 women with osteoporosis in comparison with age- and sex-adjusted normal range (105 women). Shaded areas represent 5th and 95th percentile range of normals. Patients with osteoporosis are indicated by the dots. Note incomplete separation of the two populations. Spinal measurements result in the best distinction of patients with osteoporosis from normal subjects because this disease primarily affects trabecular bone of the spine.
- FIG. 2 Fracture threshold for spinal bone mineral (horizontal line) superimposed on normal range (shaded area) and values for 76 patients with osteoporosis (dots), as depicted in FIG. 1 . With progressing age, values of increasing numbers of normal subjects are below the fracture threshold. Fracture threshold is approximately two standard deviations below mean bone mass at 35 years of age.
- FIGS. 1 and 2 are taken from Mayo Clin. Proc., Vol. 60, December 1985, mentioned above, and are based on data from Riggs B L, Wahner H W, Dunn W L, Mazess R B, Offord K P, Melton L J III: Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis, J. Clin. Invest. 67:328-335, 1981.
- FIG. 3 A. Normal male values for vertebral cancellous mineral content by QCT, using cubic regression with 95% confidence intervals. The cubic regression gives only a slightly better fit to the data for men than does a linear regression (p ⁇ 0.15).
- FIG. 4. A and B. The accuracy of single-energy QCT is shown for vertebral specimens (preserved in sodium azide) from 11 patients (10 men and 1 woman), ages 40-90 years.
- FIG. 5 Values for men with idiopathic osteoporosis and spinal fractures are plotted (black dots) against the normal male curve (cubic regression with 95% confidence intervals). A fracture threshold at approximately 11 mg/cm 3 is observed.
- FIG. 6 Idiopathic osteoporotic male values showing larger decrement from normal for vertebral mineral QCT than for mean peripheral cortical mineral by radiogrammetry and photon absorptiometry.
- FIGS. 3-6 are taken from Orthopedic Clinics of North America, Vol 16 No 3, July 1985, mentioned above.
- aqueous solution of IGF-I is added, in the amount indicated to the respective dry ampules set forth below.
- the solution is then lyophilized to result in the dry ampules for reconstitution.
- the ampules are reconstituted with the indicated amount of sterile water, physiologic saline, 0.1 M acetic acid, or 5% aqueous dextrose to result in a reconstituted solution having the total volume as shown below.
- Each vial is sufficient for a 6 day course of treatment for the intended patient.
- Ex 1 Ex 2
- Ex 3 ampule size 5 ml 8 ml 50 ml IGF-I fill volume 1 ml 5 ml 30 ml reconstitution volume 1 ml 5 ml 30 ml
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for the treatment or prevention of osteoporosis in higher mammals is disclosed, the method comprising administering Insulin-like Growth Factor I (IGF-I) in an effective amount thereof to said mammal, said mammal being in need of said treatment or prevention. Compositions for pharmaceutical use in the above method are also described.
Description
This application is a continuation of application Ser. No. 07/850,545, filed Mar. 13, 1992 now abandoned.
The present invention concerns a method for the treatment of higher mammals having or being at substantial risk of developing osteoporosis in cortical bone, the treatment comprising the administration of insulin-like growth factor I (IGF-I). Hence, the invention is directed to the fields of bone growth and degeneration, to IGF-I, and to compositions thereof for use as pharmaceuticals.
Osteoporosis encompasses a broad range of clinical syndromes having varying etiologies. In postmenopausal women, for example, two distinct types of osteoporsis have been identified. Type I osteoporosis occurs mainly in the early postmenopausal period from about age 50-65. It is characterized by excessive resorption, primarily in trabecular bone. Vertebral fractures are common. If given prior to significant bone loss, treatment which decreases or prevents bone resorption (such as with estrogen or calcitonin) is considered effective therapy.
Type II osteoporosis (a.k.a. senile osteoporosis) occurs essentially in all aging women and, to a lesser extent, in men. It is characterized by proportionate loss of cortical bone as well as trabecular bone. Here decreased bone formation plays a major role, if not a more important role than increased bone resorption. Fractures of the hip are characteristic of this type of osteoporosis.
Currently approved therapeutic agents for osteoporosis are antiresorptives. As such, while they may prevent further loss in patients with Type I osteoporosis, they are not as effective in reversing osteoporosis of either Type I or Type II or in halting Type II osteoporsis. See The American Journal of Medicine, Vol. 91 (Suppl 5B) 37S-41S; The American Journal of Medicine, Vol. 91 (Suppl 5B) 10S-13S; and The American Journal of Medicine, Vol. 91 (Suppl 5B) 23S-28S. In addition, the most widely accepted preventive agent for osteoporosis currently in use is estrogen therapy, which is not really an acceptable therapeutic agent for women with a history of or at risk for breast or endometrial cancers (estrogen dependent tumors) or for men with osteoporosis.
Insulin-like Growth Factor I (IGF-I) is a 70 amino acid peptide belonging to a family of compounds under the class name somatomedins and retains some structural and biologically similarities to insulin. The somatemedins' activity lie on a spectrum from hypoglycemic effects similar to insulin to growth promoting effects which are exemplified by growth hormone. IGF-I predominately induces growth and cell proliferation. IGF-I has also been demonstrated to specifically bind to receptors on rat osteoblast-like bone cells (Bennett et al, Endocrin. 115(4):1577-1583, 1984). IGF-I is routinely fabricated in the liver and released for binding to carrier proteins in the plasma (Schwander et al, Endocrin. 113(1):297-305, 1983), which bound form is inactive. In addition, there is a biofeedback regulating loop involving the somatomedins and growth hormone such that higher somatomedin concentrations inhibit growth hormone release which results in lesser production of endogenous IGF-I.
IGF-I infused into rats has been shown to result in markedly greater increases in body weight gain compared to controls, with increases in tibial epiphyseal width and thymidine incorporation into costal cartilage (Nature 107: 16-24, 1984) and directly stimulate osteoblasts to result in a greater number of functional osteoblasts. IGF-I is also mentioned as the vehicle through which growth hormone's effects on bone is mediated in Simpson, Growth Factors Which Affect Bone, Physiol. 235, TIBS, December 12, 1984.
Nevertheless, it is important to note that the foregoing pre-clinical studies were conducted with fetal or newborn rat cells. It is highly likely that such “young” cells are more responsive to IGF-I (as well as other influences) than older cells, especially those in the elderly with established osteoporosis or those with drug induced or environmentally induced defects leading to reduced bone density. Furthermore, in J. Bone and Mineral Res., Vol 6, Suppl 1, Abstr. 549, p. S-221, August 1991, the authors report that IGF-I has virtually no effect on cortical bone of oovariectomized rats.
Accordingly, an object of the present invention is to provide a method of treatment of osteoporosis in higher mammals exhibiting decreased cortical bone mineral density and preventing osteoporosis due to cortical bone mineral density reduction in such mammals clinically prone to such cortical bone density reductions.
Another object of the invention is to provide pharmaceutical compositions useful in achieving the foregoing object.
Surprisingly, these and other objects of the invention have been achieved with the finding that IGF-I is useful in the treatment of osteoporosis in higher mammals exhibiting decreased cortical bone mineral density and those exposed to drugs or environmental conditions which tend to result in cortical bone mineral density reduction and potentially to a cortical bone osteoporotic condition.
The present invention concerns osteoporosis treatment and prevention, which osteoporosis is associated with decreased cortical bone mineral density in mammals generally, but is especially suited for the treatment and prevention of such osteoporosis in humans.
For the present invention purposes, mammals includes all mammals within the taxonomic orders of Primates, Carnivora, Perissodactyla and Artiodactyla. This includes, without limitation, Old World monkeys, New World monkeys, great apes, humans, cats, dogs, horses, pigs, cattle, sheep, and goats. Preferably mammals are selected from the taxonmic orders of Primates, Carnivora, Perissodactyla, and Artiodactyla, more preferably Primates, cats, dogs, sheep, goats, horses, pigs and cattle, still more preferably Primates, most preferably humans.
IGF-I is a naturally occuring protein that can be obtained from a number of sources. Preferably, IGF-I from the same species (or its synthetic twin) as the species being treated therewith is employed, but IGF-I from one species may be used to treat another species if the immune response elicited is slight or non-existent. In addition, fragments and analogs of IGF-I having IGF-I activity, particularly IGF-I anti-osteoporosis activity, are also suitably employed in the invention. As used within the context of the present invention IGF-I includes such fragments and analogs unless the text clearly states otherwise. Where weights of IGF-I are presented, that weight of IGF-I or an approximately equipotent weight of such analogs and fragments are intended absent clear direction to the contrary. Where no type of IGF-I is indicated, reference is to human-IGF-I (meaning the structure, not the species source), unless the reasonable reading of the text requires otherwise.
IGF-I analogs and fragments of IGF-I or its analogs are commonly known in the art as can be seen from Proc. Natl. Acad. Sci. USA, Vol 83, pp. 4904-4907, July 1986; Biochemical and Biophysical Research Communications, Vol 149, No. 2, pp. 398-404, Dec. 16, 1987; Biochemical and Biophysical Research Communications, Vol. 149, No. 2, pp. 672-679, Dec. 16, 1987; Endocrinology, Vol. 123, No. 1, pp. 373-381; The Journal of Biological Chemistry, Vol. 263, No. 13, pp. 6233-6239, May 5, 1988; and Biochemical and Biophysical Research Communications, Vol. 165, No. 2, pp. 766-771, Dec. 15, 1989.
IGF-I can be synthetically produced, chemically or by recombinant techniques, as well as extracted from tissues. Recombinant manufacture is preferred. One such recombinant technique is disclosed in EP 123,228, incorporated herein by reference.
An effective amount of IGF-I for the present invention is an amount sufficient to slow, stop, or reverse the cortical bone mineral density reduction rate in a patient exhibiting cortical bone mineral density reduction. Throughout the specification where values are given for non-cortical bone tissue they are for purposes of exemplifying the osteoporotic state generally. In the normal healthy 20-25 year old human population, bone mineral density in the spine (using dual photon densitometry) typically is in the range of 0.85 to 1.9 g/cm3, usually 0.9 to 1.85 g/cm3, and most 1.0 to 1.8 g/cm3; and in the mid radius and distal radius it is typically 0.7-1.4 g/cm3, usually 0.75-1.3 g/cm3, and most often 0.8-1.2 g/cm3. Exemplary non-limiting normal ranges are shown in the Figures along with osteoporosis distributions. Norms using other techniques will be apparent from the literature and general experience therewith as experience with such techniques grow. Of course, it is to be remembered that different sub-populations have different norms in bone mineral density. For example, caucasian women typically differ in this parameter from caucasion men as well as from black women, oriental women, and women of other racial types. It is also important to remember that the present invention is directed to treating those with bone mineral which is (a) totally below either the normal bone mineral density range for the population generally or for the patient sub-population or (b) below 1.0 g/cm3 or (c) below the fracture threshold (approximately 2 standard deviations below the mean bone mass for the population at age 35). The fracture threshold for the spine, for example, is defined as the bone mineral density value below which 90% of all patients with one or more compression fractures of the spine are found. (See Mayo Clin. Proc., December 1985, Vol 60, p. 829-830). In addition, anyone who demonstrated a statistically significant reduction in bone density over a previous measurement, regardless of where that patient is in the typical ranges above, is a patient to whom the present invention treatment is directed. Statistical significance in this context will vary with the technique employed to measure bone mineral density, as well as with the sensitivity of the instruments used. However, with instrumentation and techniques generally available in 1988, a 1 or 2% change in bone mineral density from the earliest measurement to the most recent is not considered statistically significant. Still as techniques and equipment improve, persons of ordinary skill in the field of bone mineral density measurement will revise downward the maximum percent change which is not considered statistically significant.
Current bone mineral density measurement techniques include dual energy radiography, quantitative computerized tomography, single photon densitometry, and dual photon densitometry. These techniques will be well known to those of ordinary skill in the art; however, descriptions thereof can be found in: Mayo Clin. Proc., December 1985, Vol. 60, p. 827-835; Orthopedic Clinics of North America, Vol. 16, No. 3, July 1985, p. 557-568; Hologic QDR™-1000 Product Literature; Annals of Internal Medicine, 1984, 100:908-911; and Clinical Physiol 4:343, 1984.
Notwithstanding the lack of statistical significance of a particular result, any bone mineral density reduction should be followed for further reductions, which cumulatively may be significant.
Usually, an effective amount of IGF-I, when given parentally (intravenously, subcutaneously, intramuscularly, etc.) is between 2.5 μg/Kg/day up to about 180 μg/Kg/day, preferably about 5μg/Kg/day up to about 150 μg/Kg/day, more preferably 10 μg/Kg/day up to about 120 μg/Kg/day, even more preferably 10 μg/Kg/day up to about 100 μg/Kg/day, still more preferably about 10 μg/Kg/day up to about 90 μg/Kg/day. When given continuously, such effective amount may be given in two or three doses spread over time such as by IV drip or subcutaneous injection(s) with the total daily dose being spread across a portion or the entire administration period. Typical continuous dosing is in the range of 2.5 μg/Kg/hour up lto about 50 μg/Kg/hour, preferably about 5 μg/Kg/hour up to about 25 μg/Kg/hour, although wider ranges of “continuous” administration amounts will be apparent to those of ordinary skill in the art. When given by subcutaneous injection, it is most preferably administered from 2 times/wk up to 3 times a day, preferably 3 times a week up to once or twice daily. Particularly suitable doses are 10, 15, 30, and 60 μg/Kg/day.
The specific dosage for a particular patient, of course, has to be adjusted to the degree of response, route of administration, the individual weight and general condition of the patient to be treated, and is finally dependent upon the judgment of the treating physician.
In general, the pharmaceutical preparations for use in the present invention comprise an effective amount of IGF-I or an active fragment or analog or fragment of an analog thereof together with a pharmaceutically and parentally acceptable carrier or adjuvant. Compositions having an approximately 6 day supply typically contain from about 0.1 mg to 15 mg, preferably 1 mg to 13 mg, more preferably about 3 mg to about 10 mg, most preferably 5 mg to 10 mg of IGF-I. The liquid carriers are typically sterile water, approximately physiologic saline, about 0.1 M acetic acid, approximately 5% aqueous dextrose, etc; preferably sterile water, physiologic saline, or 5% aqueous dextrose.
The carriers and adjuvants may be solid or liquid and may be organic or inorganic. The active compound and the compositions of the invention are preferably used in the form of preparations or infusions for parenteral (subcutaneous, intramuscular, or intravenous) administration. Such solutions are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example by reconstituting a lyophilized preparation of the active agent. The pharmaceutical preparations may be sterilized and/or contain adjuvants, for example preservatives, antiinfectives, stabilizers wetting agents, emulsifiers, solubilizers, tonicity regulating agents, and/or buffers. Other adjuvants will of course be apparent to those of ordinary skill in the art. Other dosage forms and routes of administration for use in the present invention include aerosols and sprays for lung inhalation or as a nasal spray, transdermal patch administration, and buccal administration.
The present pharmaceutical preparations, which, if desired, may contain further pharmacologically active or otherwise pharmaceutically valuable substances, especially bone antiresorptives such as estrogen, calcitonin, and bisphosphonates, particularly 3-aminopropyl-1hydroxy-1, 1-bisphosphonate, are prepared from their constituent parts by techniques known in the art, for example lyophilization, dissolution, reconstitution, and suspension techniques, among others known to those of ordinary skill. They typically contain from about 0.1% to about 100% of active ingredient, but especially in the case of a solution from about 1% to about 20% and especially in the case of a lyophilizate up to 100% of active ingredient.
FIG. 1. Bone mineral density (BMD in spine (1A); (L1-4; measured with use of dual-photon absorptiometry)), midradius (1B), and distal radius (1C) (measured with use of single-photon absorptiometry) in 76 women with osteoporosis in comparison with age- and sex-adjusted normal range (105 women). Shaded areas represent 5th and 95th percentile range of normals. Patients with osteoporosis are indicated by the dots. Note incomplete separation of the two populations. Spinal measurements result in the best distinction of patients with osteoporosis from normal subjects because this disease primarily affects trabecular bone of the spine.
FIG. 2. Fracture threshold for spinal bone mineral (horizontal line) superimposed on normal range (shaded area) and values for 76 patients with osteoporosis (dots), as depicted in FIG. 1. With progressing age, values of increasing numbers of normal subjects are below the fracture threshold. Fracture threshold is approximately two standard deviations below mean bone mass at 35 years of age.
FIGS. 1 and 2 are taken from Mayo Clin. Proc., Vol. 60, December 1985, mentioned above, and are based on data from Riggs B L, Wahner H W, Dunn W L, Mazess R B, Offord K P, Melton L J III: Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis, J. Clin. Invest. 67:328-335, 1981.
FIG. 3. A. Normal male values for vertebral cancellous mineral content by QCT, using cubic regression with 95% confidence intervals. The cubic regression gives only a slightly better fit to the data for men than does a linear regression (p<0.15). B. Normal female values for vertebral cancellous mineral content by QCT, using cubic regression with 95% confidence intervals (p<0.05). An accelerated loss is observed after menopause.
FIG. 4. A and B. The accuracy of single-energy QCT is shown for vertebral specimens (preserved in sodium azide) from 11 patients (10 men and 1 woman), ages 40-90 years.
FIG. 5. Values for men with idiopathic osteoporosis and spinal fractures are plotted (black dots) against the normal male curve (cubic regression with 95% confidence intervals). A fracture threshold at approximately 11 mg/cm3 is observed.
FIG. 6. Idiopathic osteoporotic male values showing larger decrement from normal for vertebral mineral QCT than for mean peripheral cortical mineral by radiogrammetry and photon absorptiometry.
FIGS. 3-6 are taken from Orthopedic Clinics of North America, Vol 16 No 3, July 1985, mentioned above.
Having fully described the instant invention, the following Examples are presented to more clearly set forth the invention without imposing any limits on the scope of the invention as set out in the claims.
Sterile, filtered 1% (w/v) aqueous solution of IGF-I is added, in the amount indicated to the respective dry ampules set forth below. The solution is then lyophilized to result in the dry ampules for reconstitution. The ampules are reconstituted with the indicated amount of sterile water, physiologic saline, 0.1 M acetic acid, or 5% aqueous dextrose to result in a reconstituted solution having the total volume as shown below. Each vial is sufficient for a 6 day course of treatment for the intended patient.
|
Ex 2 | Ex 3 | ||
|
5 |
8 |
50 ml | ||
IGF-I fill |
1 |
5 |
30 | ||
reconstitution volume | |||||
1 |
5 |
30 ml | |||
6 beagles per group are used to demonstrate the ability of IGF-I to improve cortical bone density after loss of ovarian function. One group is given a sham operation to serve as a control. 4 other groups are oophorectomized. Of these 4, one group is treated with IGF-I immediately, one is given IGF-I after bone growth function has been reduced, one is treated with estrogen and one is followed without treatment. Each group is followed for a period of 12 months and bone mineral density (BMD) of the vertibral (trabecular) and femoral (cortical) bones are measured. The results, reported as average changes per group over the 8 month period are reported in Table I below.
TABLE I | ||
% CHANGE IN BMD | % CHANGE IN BMD | |
TREATMENT | (12 MONTHS-0 TIME) | (12 MONTHS-0 TIME) |
GROUP | CORTICAL BONE | TRABECULAR BONE |
Sham Operation | 4.0% | 6.2% |
Oophorectomized | 0.4% | −1.4% |
only | ||
Oophorect. + imm. | 10.1% | 12.3% |
IGF-I | ||
Oophorect. + estrog. | ||
4 months treatment | ||
after 8 months delay | 1.9% | 8.8% |
Oophorect. + IGP- |
||
4 months treatment | ||
after 8 months delay | 9.6% | 9.0% |
Not only did the treatment with IGF-I both prophylactically and therapeutically completely wipe out any loss in cortical bone growth associated with oophorectomy, it pushed cortical bone growth beyond the levels which were achieved by the sham operated controls by more than twice those values and beyond that acheived by estrogen by more than 4.5 times.
Claims (12)
1. A method for the treatment of osteoporosis in a mammal having reduced cortical bone mineral density or preventing the same in a mammal prone thereto comprising administering to said mammal an effective amount for said treatment or prevention of a compound selected from IGF-I, an active fragment thereof, an active analog thereof, or an active fragment of either IGF-I or its analog.
2. The method of claim 1 wherein said mammal is a human being.
3. The method of claim 1 wherein said IGF-I has the same amino acid sequence as natural IGF-I for the same species as the species to which said IGF-I is being administered.
4. The method of claim 1 wherein said compound is a naturally occurring.
5. The method of claim 1 wherein said compound is synthetically produced.
6. The method of claim 1 wherein said compound is produced by a recombinant technique.
7. The method of claim 1 wherein said compound is administered parenterally.
8. The method of claim 1 wherein said reduction in cortical bone mineral density in said mammal is in excess of 2% of any prior cortical bone mineral density measurement in said mammal.
9. The method of claim 1 wherein said reduction in cortical bone mineral density in said mammal is in excess of 4% of any prior cortical bone mineral density measurement in said mammal.
10. The method of claim 1 wherein said reduction in cortical bone mineral density in said mammal is in excess of 6% of any prior cortical bone mineral density measurement in said mammal.
11. The method of claim 1 wherein said reduced cortical bone mineral density is characterized as being at or below the lower 10th percentile of the general population of mammals of the same species between the ages of 1.5 times and twice reproductive maturity for said species.
12. The method of claim 11 wherein said mammal is a human being and said 1.5 times to twice reproductive maturity is the age bracket 20-25 years.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/243,520 US6300309B1 (en) | 1992-03-13 | 1994-06-01 | Method and composition for the treatment of osteoporosis |
US09/703,853 US6358925B1 (en) | 1992-03-13 | 2000-11-01 | Method and composition for the treatment of osteoporosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85054592A | 1992-03-13 | 1992-03-13 | |
US08/243,520 US6300309B1 (en) | 1992-03-13 | 1994-06-01 | Method and composition for the treatment of osteoporosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US85054592A Continuation | 1992-03-13 | 1992-03-13 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/703,853 Continuation US6358925B1 (en) | 1992-03-13 | 2000-11-01 | Method and composition for the treatment of osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
US6300309B1 true US6300309B1 (en) | 2001-10-09 |
Family
ID=25308435
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/243,520 Expired - Fee Related US6300309B1 (en) | 1992-03-13 | 1994-06-01 | Method and composition for the treatment of osteoporosis |
US09/703,853 Expired - Fee Related US6358925B1 (en) | 1992-03-13 | 2000-11-01 | Method and composition for the treatment of osteoporosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/703,853 Expired - Fee Related US6358925B1 (en) | 1992-03-13 | 2000-11-01 | Method and composition for the treatment of osteoporosis |
Country Status (11)
Country | Link |
---|---|
US (2) | US6300309B1 (en) |
EP (1) | EP0560723A1 (en) |
JP (1) | JP3771280B2 (en) |
KR (1) | KR930019223A (en) |
AU (1) | AU666514B2 (en) |
CA (1) | CA2091534A1 (en) |
IL (1) | IL104940A0 (en) |
MX (1) | MX9301387A (en) |
NZ (1) | NZ247123A (en) |
TW (1) | TW267102B (en) |
ZA (1) | ZA931778B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996007744A1 (en) * | 1994-09-08 | 1996-03-14 | Chiron Corporation | A method of improved production of insulin-like growth factor |
US5728676A (en) * | 1994-09-08 | 1998-03-17 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
JP3971108B2 (en) | 1999-01-06 | 2007-09-05 | ジェネンテック・インコーポレーテッド | Insulin-like growth factor (IGF) I mutant |
JP2003528149A (en) | 2000-03-24 | 2003-09-24 | ジェネンテック・インコーポレーテッド | Use of insulin for the treatment of cartilage disorders |
EP1282437B1 (en) | 2000-05-16 | 2008-03-19 | Genentech, Inc. | Treatment of cartilage disorders |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
US8158582B2 (en) * | 2005-06-02 | 2012-04-17 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 deficiency |
EP1984016A1 (en) * | 2006-02-17 | 2008-10-29 | Associazione Foresta Per La Ricerca Nella Riproduzione Umana | Use of insulin-like factor 3 for treating osteoporosis and bone disorders |
US20080200425A1 (en) * | 2007-02-16 | 2008-08-21 | Kurtz Seymour J | Methods and compositions for regulating bone mineral density |
CA3059593A1 (en) * | 2017-05-21 | 2018-11-29 | Igf Oncology, Llc | An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123228A2 (en) | 1983-04-25 | 1984-10-31 | Chiron Corporation | Hybrid DNA synthesis of mature insulin-like growth factors |
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
EP0289314A2 (en) | 1987-04-28 | 1988-11-02 | Roche Diagnostics GmbH | Use of IGF-II in the treatment of bone disorders |
EP0318184A1 (en) | 1987-11-12 | 1989-05-31 | Schering Corporation | Acceleration of bone formation with GM-CSF |
US4861757A (en) * | 1986-11-14 | 1989-08-29 | Institute Of Molecular Biology | Wound healing and bone regeneration using PDGF and IGF-I |
EP0434625A2 (en) | 1989-12-22 | 1991-06-26 | Ciba-Geigy Ag | IGF-I for treating adverse effect of steroid therapy |
EP0436469A1 (en) | 1990-01-03 | 1991-07-10 | Ciba-Geigy Ag | Composition and method for the treatment of osteoporosis in mammals |
EP0440989A1 (en) | 1990-01-05 | 1991-08-14 | Fujisawa Pharmaceutical Co., Ltd. | A method for preparing a dried composition of insulin-like growth factor I (IGF-I) |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
-
1993
- 1993-02-22 TW TW082101222A patent/TW267102B/zh active
- 1993-03-04 EP EP93810161A patent/EP0560723A1/en not_active Ceased
- 1993-03-04 IL IL104940A patent/IL104940A0/en unknown
- 1993-03-09 AU AU34068/93A patent/AU666514B2/en not_active Ceased
- 1993-03-11 KR KR1019930003607A patent/KR930019223A/en not_active Application Discontinuation
- 1993-03-11 CA CA002091534A patent/CA2091534A1/en not_active Abandoned
- 1993-03-11 NZ NZ247123A patent/NZ247123A/en unknown
- 1993-03-12 JP JP05172793A patent/JP3771280B2/en not_active Expired - Fee Related
- 1993-03-12 ZA ZA931778A patent/ZA931778B/en unknown
- 1993-03-12 MX MX9301387A patent/MX9301387A/en unknown
-
1994
- 1994-06-01 US US08/243,520 patent/US6300309B1/en not_active Expired - Fee Related
-
2000
- 2000-11-01 US US09/703,853 patent/US6358925B1/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
EP0123228A2 (en) | 1983-04-25 | 1984-10-31 | Chiron Corporation | Hybrid DNA synthesis of mature insulin-like growth factors |
US4861757A (en) * | 1986-11-14 | 1989-08-29 | Institute Of Molecular Biology | Wound healing and bone regeneration using PDGF and IGF-I |
EP0289314A2 (en) | 1987-04-28 | 1988-11-02 | Roche Diagnostics GmbH | Use of IGF-II in the treatment of bone disorders |
EP0318184A1 (en) | 1987-11-12 | 1989-05-31 | Schering Corporation | Acceleration of bone formation with GM-CSF |
EP0434625A2 (en) | 1989-12-22 | 1991-06-26 | Ciba-Geigy Ag | IGF-I for treating adverse effect of steroid therapy |
EP0436469A1 (en) | 1990-01-03 | 1991-07-10 | Ciba-Geigy Ag | Composition and method for the treatment of osteoporosis in mammals |
EP0440989A1 (en) | 1990-01-05 | 1991-08-14 | Fujisawa Pharmaceutical Co., Ltd. | A method for preparing a dried composition of insulin-like growth factor I (IGF-I) |
US5210074A (en) * | 1990-01-05 | 1993-05-11 | Fujisawa Pharmaceutical Co., Ltd. | Method for preparing a dried composition of insulin-like growth factor i |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
Non-Patent Citations (38)
Title |
---|
Abstract #548, p. S221 of Kalu et al, Insulin-Like Growth Factor-I Partially Prevents Ovarietomy Enduced Bone Loss, Aug. 26, 1991. |
Abstract #549, p. S 221 of Mueller et al, Insulin-Like Growth Factor-I increases Trabecular Bonemass in the Ovariectomized Rats, Aug. 26, 1991. |
Ballard et al, Biochemical And Biophysical Res. Commun. vol. 149, No. 2, 398-404, 1988. |
Bayne et al, J. Biolocical Chemistry, vol. 263, No. 13, 6233-6239 (1988). |
Bennett et al, Characterization of Insulin-Like Growth Factor I . . . , Endocrinology vol. 115, No. 4, 1577-1583 (1984). |
Bennett et al, J. Clinical Endocrinology & Metabolism, vol. 59, No. 4, 701-704 (1984). |
Buul-Offers. et al, Pediatric Research vol. 20, No. 9, 825-827, 1986. |
CA: 115(14) #142160u-Stephan et al. Oct. 1991.* |
CA: 115(22) #239741X-Buerk Dec. 1991.* |
Canalis et al, Metabolism, vol. 26, No. 10, (Oct. 1977) 1079-1087. |
Canalis, J. Clin. Invest., vol. 66, Oct. 1980, 709-719. |
Cascieri et al, Endocrinology, vol. 123, No. 1, 373-381 (1988). |
Chem Abstract 108:50024e, 1988 of Hoek et al, Endocrinology 122(1), 254-260 (1988). |
Chiron Corp. Annual Report 1987 (1 page). |
Conover et al, Insulin-Like Growth Factor I/Somatomedin-C and Glucocorticoids Synergistically; J. Cellular Physiolegy 116: 191-197(1983). |
Gotfredson et al, Total Body Bone Mineral in Vivo by Dual Photon Absorptiometry, Clinical Physiology (1984) 4, 343-355. |
Guler et al, Proc. Natl. Acad. Sci. USA, vol. 85, 4889-4893 (Jul. 1988). |
Heaney, American J. of Medicine, vol. 91 (Suppl 5B) 23S-28S (Nov. 1991). |
Humbel, Rene E., (1990) "Insulin-Like Growth Factors I and II" Eur. J. Biochem. 190:445-462. |
Isgaard et al, Am. J. Physiol. 250 (Endocrinol. Metab. 13): E. 367-E 372, 1986. |
Kimmel, Radiologic Methods . . . , Annals Internal Medicine 1984, 100:908-911. |
Lindsay, American J. of Medicine, vol. 91 (Suppl. 5B) 10S-13S (Nov. 1991). |
Merimee, Thomas J., (1987) "Insulin-Like Growth Factors in Pygmies" The New England Journal of Medicine 316(15):906-911. |
Ott, Annals of Internal Medicine, vol. 104, No. 6, Jun. 1986, 874-876. |
QDR-1000 Product Literature (6 pages) (1989). |
Raisz, New England Journal of Medicine, vol. 318, No. 13, p. 818-828 (1988). |
Riggs, American J. of Medicine, vol. 91(Suppl. 5B) 375-415 (Nov. 1991). |
Russel et al, Endocrinology 116:2563-2567 (1985). |
Sara et al, Biochemical And Biophysical Res. Commun. vol. 165, No. 2, 766-771 (1989). |
Sara et al, Proc. Natl. Acad. Sci. USA, vol. 83, 4904-4907, (Jul. 1986). |
Schoenle et al, Insulin-Like Growth Factor I Stimulates Growth in Hypophysectomized Rats, Nature vol.296, No. 5484, 252-253(1982). |
Schwander et al, Synthesis And Secretion of Insulin-Like Growth Factor . . . , Endocrinology vol. 113, No. 1, 297-305 (1983). |
Seyodin et al, J. Bioldgical Chemistry vol. 261, No. 13, 5693-5695 (1985). |
Simpson, Physiol. 235, E613-E616, Dec. 1984, Growth Factors Which Affect Bone. |
Stedmans Medical Dictionary 24th Ed. 1982, p. 1301, 1302. |
Stracke et al, Effect of Growth Hormone on Osteoblasts And Demonstration of Somatomedin-C/IGFI in Bone Organ Culture, Acta Endocrinologia 1984, 107:16-24. |
Tashjian et al, Proc. Natl. Acad. Sci. USA, vol. 82, 4535-4538 (Jul. 1985). |
Tseng et al, Biochemical And Biophysical Res. Commun. vol. 149, No. 2, 672-679, 1988. |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8197854B2 (en) | 2005-08-04 | 2012-06-12 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263667B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
Also Published As
Publication number | Publication date |
---|---|
TW267102B (en) | 1996-01-01 |
CA2091534A1 (en) | 1993-09-14 |
KR930019223A (en) | 1993-10-18 |
US6358925B1 (en) | 2002-03-19 |
AU3406893A (en) | 1993-09-16 |
NZ247123A (en) | 1997-08-22 |
MX9301387A (en) | 1994-08-31 |
AU666514B2 (en) | 1996-02-15 |
EP0560723A1 (en) | 1993-09-15 |
JPH069429A (en) | 1994-01-18 |
ZA931778B (en) | 1993-09-13 |
JP3771280B2 (en) | 2006-04-26 |
IL104940A0 (en) | 1993-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6174857B1 (en) | Composition and method for the treatment of osteoporosis in mammals | |
US6300309B1 (en) | Method and composition for the treatment of osteoporosis | |
EP0571417B1 (en) | Combination of igf-i and igfbp for anabolism | |
AU645874B2 (en) | Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH) | |
US5681814A (en) | Formulated IGF-I Composition | |
US20110105390A1 (en) | Selection and treatment of patients suffering from wasting | |
NZ241108A (en) | Use of insulin-like growth factor and medicaments thereof in promoting cardiac muscle synthesis and preventing/treating heart disorders | |
CA2142455A1 (en) | Method for systemic treatment of catabolic conditions and systemic tissue injury | |
Kirkeby et al. | No effects of local somatomedin C on bone repair: Continuous infusion in rats | |
JPH10502368A (en) | Use of insulin and IGF-I | |
US20040242489A1 (en) | Method for improving stability of a bone-connecting implant | |
Kirkeby et al. | No effect of systemic administration of somatomedin C on bone repair in rats | |
US5246700A (en) | Pharmaceutical compositions for treating bone disorders | |
Isaksson et al. | Direct action of GH | |
EP1767213A2 (en) | Method for improving stability of a bone-connecting implant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GULER, HANS-PETER;BHATIA, SATISH;REEL/FRAME:011901/0088 Effective date: 19920506 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131009 |